Nezarali Moulaei, Seyyed Mohammad Ali Mirjahanbakhsh, Mohammad Kazem Momeni, Mosayeb Shahryar, Hossein Ansari

Abstract

Introduction: Asthma is a chronic respiratory symptom that causes inflammation, hypersensitivity, and spasm of the airways. Asthma is one of the most common chronic diseases in the world. It is estimated that there are 235 million asthma patients in the world. Therefore, the present study aimed to evaluate the effectiveness of tiotropium bromide on severe asthma patients. Methods: The present study was a Randomized Placebo-Controlled Crossover Trial. The study population were the 60 patients referred to the Respiratory Department of the Ali ibn Abi Talib in Zahedan. The patients were divided into placebo and experimental groups. Tiotropium bromide was prescribed in combination with the routine treatment in the experimental group. After four weeks, the FEV1 level and the score of the Asthma Control Test (ACT) were evaluated, and the groups were interchanged after a washout period of 4 weeks. Then the placebo group received tiotropium bromide, and the tiotropium bromide group received the placebo; and after four weeks, the FEV1 level and the score of the ACT were re-evaluated. Tiotropium bromide and the placebo were coded, making the study a double-blind one. Finally, the data were statically analyzed using SPSS. Results: The results showed that In the tiotropium bromide group, 14 (46.7 %) of the patients were male, and 16 (53.3 %) of them were female, and in the placebo group, 16 (53.3 %) of the patients were male, and 14 (46.7 %) were females. The mean age in the tiotropium bromide and the placebo groups was 26.366 ± 7.430 and 30.266 ± 8.423, respectively. The period of the disease in the tiotropium bromide and the placebo groups was 3.036 ± 4.766 and 3.002 ± 3.866, respectively. Finally, our results showed that tiotropium bromide has a role in controlling asthma and improving the mean FEV1. Conclusion: The researchers of this study found tiotropium bromide to be beneficial in the treatment of severe asthma patients. Moreover, adding tiotropium to the asthma treatment regimen was found to be beneficial in lowering the dosage of corticosteroids.